EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU)

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 17, 2024

Primary Completion Date

October 1, 2024

Study Completion Date

October 31, 2024

Conditions
Acute Decompensated Heart Failure
Interventions
DEVICE

Reprieve Decongestion Management System

The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.

DRUG

Diuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide)

Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).

Trial Locations (2)

Unknown

University Medical Center Groningen, Groningen

Wroclaw Medical University, Wroclaw

All Listed Sponsors
lead

Reprieve Cardiovascular, Inc

INDUSTRY

NCT06362668 - EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU) | Biotech Hunter | Biotech Hunter